MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION IN ADULTS RECEIVING ANTI-COAGULANTS

Similar documents
Appendix 3 PCC Warfarin Reversal

Guidelines for the management of warfarin reversal in adults

Major Haemorrhage Protocol. Commentary

ANTICOAGULATION RELATED BLEEDING - GUIDELINE SUMMARY

Active date July Ratification date: Review date January 2014 Applies to: Staff managing patients on warfarin. Exclusions:

Protamine sulphate LEO Pharma 1400 anti-heparin IU/ml solution for injection and infusion.

DATA SHEET. Product Summary. 1. Trade Name of Medicinal Product. Protamine Sulphate Injection BP. 2. Qualitative and Quantitative Composition

ADMINISTRATIVE CLINICAL Page 1 of 6

Coagulation, Haemostasis and interpretation of Coagulation tests

MANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR

Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol

Paediatric Anticoagulant Guidelines. Bhavee Patel, Gareth Thomas

Developed for Scotland by the National Plasma Product Expert Advisory Group (NPPEAG)

Pathology Service User Guide Haematology

John Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne

GUIDELINES FOR MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION WITH ORAL ANTICOAGULANTS

GUIDELINES FOR MANAGEMENT OF OVER ANTICOAGULATION WITH WARFARIN

Chapter 1 The Reversing Agents

North East Essex Medicines Management Committee

ADVOCATE HEALTHCARE GUIDELINE FOR ANTITHROMBOTIC REVERSAL

Blood Thinner Agent. Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy

Reversal of Anticoagulants at UCDMC

Guidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults

Anticoagulants. Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT

Guidelines for Anticoagulation in Paediatric Cardiac Patients

Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc)

MANAGEMENT OF OVER-ANTICOAGULATION. Tammy K. Chung, Pharm.D. Critical Care & Cardiology Specialist Presbyterian Hospital Dallas

When Should I Use Tranexamic Acid for Children? Dr Andrea Kelleher Consultant Adult and Paediatric Cardiac Anaesthetist

NOACS/DOACS*: COAGULATION TESTS

ANTICOAGULANTS & FIBRINOLYTIC AGENTS Chapter 34

(e.g. inclusion and exclusion criteria, diagnosis) anticoagulation Future management of HIT patients post acute phase

Treatment Options and How They Work

Use of Anticoagulant Reversal Agents

P-RMS: LT/H/PSUR/0004/001

Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture

CLINICAL GUIDELINES ID TAG

Use of Prothrombin Complex Concentrates (PCC) CONTENTS

Post-procedure dose ok after hours. 12 hours (q 24h dosing only) assuming surgical hemostasis; second dose 24 hours after first dose.

Dr Shikha Chattree Haematology Consultant Sunderland Royal infirmary

DEEP VEIN THROMBOSIS (DVT): TREATMENT

Appendix IV - Prescribing Guidance for Apixaban

MANAGEMENT OF COMMON BLEEDING DISORDERS. Auro Viswabandya Department of Haematology, CMC, Vellore

Agent Dose MoA/PK/Admin Adverse events Disadvantages Protamine Heparin: 1mg neutralizes ~ 100 units Heparin neutralization in ~ 5 min

>>FAST TRACK<< Hemostasis has three key components: platelets, the plasma coagulation. cascade, and the blood vessel wall (endothelium).

Management of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline. Contents

TRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006

Trust Guideline for the Management of: Adult patients requiring anticoagulation with Warfarin (including reversal)

Prothrombin Complex Concentrate- Octaplex. Octaplex

Patients with cancer are at a greater risk of developing venous thromboembolism than non-cancer patients, partly due to the 1

CHAPTER 17 Antithrombotic Agents Heparins

Transfusion Requirements and Management in Trauma RACHEL JACK

Title Use and monitoring of Low Molecular Weight Heparins (LMWHs) in community hospitals and community nursing Clinical Guidelines

When reconstituted as recommended, each vial of Prothrombinex -VF contains the ingredients listed in Table 1.

NURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE PROTOCOLS. ACUTE CEREBROVASCULAR ACCIDENT TPA (ACTIVASE /alteplase) FOR THROMBOLYSIS

Reversal Agents for Anticoagulants Understanding the Options. Katisha Vance, MD, FACP Alabama Oncology January 28, 2017

Anticoagulation. MPharm Programme & OSPAP Programme. Tania Jones Senior Lecturer in Pharmacy Practice & Therapeutics

Trust Guideline for the Management of: Adult patients requiring anticoagulation with Warfarin (including reversal)

The factors II, IX, X, the antithrombin III and the plasma proteins are all of human origin. The heparin sodium is of porcine origin.

When reconstituted as recommended, each vial of Prothrombinex -VF contains the ingredients. 27 mg

2. What you need to know before you are given Konakion MM. Package Leaflet: Information for the patient

Konakion MM. Phytomenadione Composition. Properties and effects. Pharmacokinetics

Prof Beverley Hunt MB ChB, FRCP, FRCPath, MD Chair of Thrombosis & Haemostasis, King s College, London Medical Director of Lifeblood: the thrombosis

Mousa Suboh. Osama Alzoubi (OZ) Malik Zuhlof. 1 P a g e

incidence of cancer-associated thrombosis (CAT) is further increased by additional risk factors such as chemotherapeutic 2

Edoxaban Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (NICE TA354)

Reversal of anticoagulation in GI Bleeding

Edoxaban for the treatment and prevention of venous thromboembolism (DVT or PE) or stroke prevention in non-valvular AF

St George Hospital Renal Department Guideline: INTERNAL ONLY ANTICOAGULATION - COMMENCEMENT OF HAEMODIALYSIS

Reference Number: Revision No: Review Cycle:

New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)

Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban

PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT

Approach to bleeding disorders &treatment. by RAJESH.N General medicine post graduate

Edoxaban For preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (NICE TA 355)

Guideline for Thrombolysis Therapy in Pulmonary Embolism

Treatment of anticoagulant-associated intracerebral haemorrhage

idarucizumab 2.5g/50mL solution for injection/infusion (Praxbind ) SMC No. (1178/16) Boehringer Ingelheim Ltd

NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.

2.5 Other Hematology Consult:

Platelet-fibrin clot. 50Kd STEMI. Abciximab. Video of a IIb/IIIa inhibitor in action. Unstable Angina and non-stsegment

Guidelines for testing and perioperative management of dabigatran and rivaroxaban

Rivaroxaban film coated tablets are available in 2 strengths for this indication: 15mg and 20mg.

Hemostasis and Blood Forming Organs

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CORE SPC FOR HUMAN PROTHROMBIN COMPLEX PRODUCTS (CPMP/BPWG/3735/02)

Appendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS

Idarucizumab for Dabigatran Reversal Pollack CV, Reilly PA, Eikelboom J, et al. N Engl J Med 2015; 373(6):

PRODUCT INFORMATION. FRAGMIN Injection Dalteparin sodium NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY. Active ingredient: Dalteparin sodium.

DVT - initial management NSCCG

Managing Coagulopathy in Intensive Care Setting

INTRODUCTION Indication and Licensing

ATLANTIC HEALTH GUIDELINES FOR ANTICOAGULANT, ANTIPLATELET, AND THROMBOLYTIC REVERSAL IN ADULT PATIENTS

Primary Care Prescriber Information EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism

Hemostasis and thrombosis in patients with liver disease. Ton Lisman, Dept Surgery, UMC Groningen, The Netherlands

Cancer and Thrombosis

What s in the Massive Transfusion Protocol (MTP) Package?

This chapter will describe the effectiveness of antithrombotic

Incorporated Dosing Guidelines: Intravenous Heparin Therapy Initial Dose

Novel Anticoagulant Drugs. by: Dr. M. Kamandi Fellowship of hematology and Oncology

Major Haemorrhage Transfusion Pathway

Transcription:

Hairmyres Hospital MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION IN ADULTS RECEIVING ANTI-COAGULANTS Bleeding in patients on anticoagulants, even in the absence of over-anticoagulation, can be life-threatening or can threaten the viability of a limb. Such bleeding should be treated as a MEDICAL EMERGENCY. All such cases should be discussed both with the consultant under whose care they are and with a consultant haematologist. To contact haematology medical staff: DECT phone 4320 Monday-Friday 9am-5pm Via Hairmyres switchboard outwith these times or on public holidays 1

MANAGEMENT OF LIFE-THREATENING BLEEDING AND BLEEDING THREATENING THE VIABILITY OF A LIMB PATIENTS ON WARFARIN (or other vitamin K antagonists) (Adapted from BCSH guidelines on oral anticoagulation (1998), available online at www.bcshguidelines.com) 1. OMIT WARFARIN 2. GIVE: a. 5 mg intravenous vitamin K (in 100ml 5% dextrose over 15-20 minutes) b. At discretion of treating medical staff and consultant haematologist, ONE of the following: i. DEFIX up to 50 iu/kg body weight plus FFP 2 units OR ii. FFP 15mls/kg body weight NOTES i. DEFIX contains factors II, IX and X. Its use should be avoided if possible in patients with severe hepatic impairment, unstable coronary syndromes or DIC. Because of a potential risk of thrombosis, these patients should instead receive FFP alone at a dose of 15 ml/kg. ii. The rationale for giving a small amount of FFP along with DEFIX is to provide factor VII, which is missing from DEFIX. iii. DEFIX and FFP will not be issued without prior discussion with the duty consultant haematologist (contact details as above) 2

MANAGEMENT OF LIFE-THREATENING BLEEDING OR BLEEDING THREATENING THE VIABILITY OF A LIMB PATIENTS ON HEPARIN If the patient is receiving intravenous (unfractionated) heparin: 1. Stop the heparin infusion (half life is approximately 1 hour but increases in overdose) 2. Give protamine sulphate by slow intravenous bolus (over 10 minutes). 1mg protamine neutralises about 100 units of heparin. Maximum dose of protamine is 50mg. See protocol for administration of protamine on pages 8 and 9 of this document. If the patient is receiving low molecular weight heparin: 1. Ensure that no further heparin is given 2. Give protamine sulphate by slow intravenous bolus (over 10 minutes). Neutralisation of low molecular weight heparin is incomplete and variable (see below). Maximum dose of protamine is 50mg. See protocol for administration of protamine on pages 8 and 9 of this document. NOTES: a. Low molecular weight heparin may not be fully neutralised by protamine. The percentage of anticoagulant activity neutralised depends on the brand of low molecular weight heparin. Crowther et al (British Journal of Haematology (2002, 3

116: 178-186) found the following percentage inactivations for different low molecular weight heparins: tinzaparin 85.7% inactivated dalteparin 74% inactivated enoxaparin 54.2 % inactivated. b. There is a small risk of anaphylaxis if patients receiving protamine have previously been exposed to this agent. 4

MANAGEMENT OF LIFE-THREATENING BLEEDING OR BLEEDING THREATENING THE VIABILITY OF A LIMB PATIENTS WHO HAVE RECEIVED THROMBOLYTIC AGENTS (STREPTOKINASE, tpa) 1. Give tranexamic acid 1g by infusion in 100 ml 5% dextrose over 15 minutes OR aprotinin 500 000 kallikrein inactivator units over 10 minutes followed by 200 000 units over 4 hours. 2. Give cryoprecipitate 10 units and/or 15 mls/kg body weight FFP to replenish depleted coagulation factors, guided by results of a coagulation screen. Reference: Ludlam et al (1995) Guidelines for the use of thrombolytic therapy. Blood Coagulation and Fibrinolysis 6: 273-285. 5

MANAGEMENT OF HIGH INR WITH OR WITHOUT MINOR BLEEDING IN PATIENTS ON WARFARIN OR OTHER VITAMIN K ANTAGONISTS (Adapted from BCSH guidelines on oral anticoagulation (1998), available on-line at www.bcshguidelines.com) 1. Patients with INR greater than or equal to 8 a. omit warfarin b. Give vitamin K: 0.5 1 mg intravenously (infuse over 15 minutes in 100 ml 5% dextrose) or 1 2 mg orally (iv preparation given orally - see notes below) for all patients. 2. Patients with INR less than 8 a. Omission of warfarin may be sufficient. b. In presence of risk factors for haemorrhage, consider administration of vitamin K, 0.5 mg intravenously (infuse over 15 minutes in 100 ml 5% dextrose) or 1 mg orally (give iv preparation orally see notes below). Risk factors for haemorrhage may include: Age >75 Severe hypertension History of significant GI bleed Recent (< 1 month) cerebrovascular accident Recent (<1 month) major surgery NOTES i. Administration of the intravenous preparation of vitamin K orally is UNLICENSED, although widely practised. 6

ii. Ensure that whoever monitors the patient s warfarin is informed AS SOON AS POSSIBLE of any change to warfarin dose and/or of need to give vitamin K. iii. Ensure that appropriate arrangements are in place for resumption of INR checks (eg next day) and that patient is aware of these. Protamine Injection Preparation Protamine sulphate is available as 10mg/ml in 5ml ampoules. Indication Protamine sulphate is used as an antidote to heparin. Dose The dose of protamine to be given depends on the type of heparin used and the length of time since the dose was given. No more than 50mg should be given in one dose. Heparin Bolus: Time elapsed since dose given Protamine dose per 100units of heparin Protamine dose for 5000units of heparin 30mins 1-1.5 mg 50mg 30-60mins 0.5-0.75mg 25-37.5mg 2 hours 0.25-0.375mg 12.5-18.75mg Heparin Infusions: Stop the infusion and give 25-50mg of protamine. Subcutaneous Heparin -including Low Molecular Weight Heparin (LMWH): One mg of protamine per 100units of heparin give 25-50mg as a slow IV injection and the remainder as a slow infusion over 8-16 hours or as 2hourly divided doses. Administration Protamine is given as a slow IV bolus over 10mins, at a maximum of 5mg/minute. If an infusion is required dilute with sodium chloride 0.9%, 100ml or 250ml bag. 7

Hypersensitivity to protamine. Contraindications Cautions/Monitoring Check activated partial thromboplastin time (APTT) 5-15minutes after giving protamine. Further doses of protamine may be required because protamine is cleared from the body quicker than heparin, especially LMWH. The anti-xa activity of LMWHs may not be completely reversed with protamine: refer to individual data sheets for further information and see also information given on pages 3 and 4 of this document. Please note the information provided is a guide for treating adult patients. Always refer to the product data sheet for full details 8